AU2019326423A1 - Collections of peptides, peptide agents, and methods of use thereof - Google Patents

Collections of peptides, peptide agents, and methods of use thereof Download PDF

Info

Publication number
AU2019326423A1
AU2019326423A1 AU2019326423A AU2019326423A AU2019326423A1 AU 2019326423 A1 AU2019326423 A1 AU 2019326423A1 AU 2019326423 A AU2019326423 A AU 2019326423A AU 2019326423 A AU2019326423 A AU 2019326423A AU 2019326423 A1 AU2019326423 A1 AU 2019326423A1
Authority
AU
Australia
Prior art keywords
amino acid
independently
collection
peptide
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019326423A
Other languages
English (en)
Inventor
John Hanney Mcgee
Mark Joseph Mulvihill
Raheleh REZAEI ARAGHI
Ty Matthew Thomson
Gregory L. Verdine
Sebastian Christof Theodor WAHL
Yue-Mei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parabilis Medicines Inc
Original Assignee
Fog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fog Pharmaceuticals Inc filed Critical Fog Pharmaceuticals Inc
Publication of AU2019326423A1 publication Critical patent/AU2019326423A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
AU2019326423A 2018-08-20 2019-08-20 Collections of peptides, peptide agents, and methods of use thereof Abandoned AU2019326423A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719996P 2018-08-20 2018-08-20
US62/719,996 2018-08-20
PCT/US2019/047206 WO2020041270A1 (en) 2018-08-20 2019-08-20 Collections of peptides, peptide agents, and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2019326423A1 true AU2019326423A1 (en) 2021-04-08

Family

ID=69591277

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019326423A Abandoned AU2019326423A1 (en) 2018-08-20 2019-08-20 Collections of peptides, peptide agents, and methods of use thereof

Country Status (14)

Country Link
US (1) US12398178B2 (enExample)
EP (1) EP3840766A4 (enExample)
JP (1) JP2021535108A (enExample)
KR (1) KR20210060482A (enExample)
CN (1) CN113039195A (enExample)
AU (1) AU2019326423A1 (enExample)
BR (1) BR112021003113A2 (enExample)
CA (1) CA3110082A1 (enExample)
EA (1) EA202190531A1 (enExample)
IL (1) IL280931A (enExample)
MA (1) MA53446A (enExample)
MX (1) MX2021001943A (enExample)
SG (1) SG11202101672YA (enExample)
WO (1) WO2020041270A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004555A2 (pt) * 2017-09-07 2020-09-24 Fog Pharmaceuticals, Inc. agentes que modulam funções de beta-catenina e métodos dos mesmos
AU2019326423A1 (en) 2018-08-20 2021-04-08 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
GB201909103D0 (en) * 2019-06-25 2019-08-07 Univ Bath Compounds
BR112023025528A2 (pt) * 2021-06-08 2024-02-27 Fog Pharmaceuticals Inc Peptídeos grampeados e métodos destes

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
CA2686827C (en) 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US10716828B2 (en) 2007-05-02 2020-07-21 Dana-Farber Cancer Institute, Inc. Methods of modulating cellular homeostatic pathways and cellular survival
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP5788178B2 (ja) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
EP3401684B1 (en) 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
EP3698811A1 (en) 2009-06-18 2020-08-26 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US20130035304A1 (en) 2010-01-29 2013-02-07 Walensky Loren D Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
AU2011274474B2 (en) 2010-07-09 2015-06-18 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
EP2637680B1 (en) 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Cancer therapies
CA2833171C (en) 2011-04-15 2021-08-31 Loren D. Walensky Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
WO2012174409A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized variant maml peptides and uses thereof
CA3173988A1 (en) 2011-10-11 2013-04-18 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic bax
WO2013102211A2 (en) 2011-12-29 2013-07-04 Walensky Loren D Stabilized antiviral fusion helices
AU2013235425B2 (en) 2012-03-20 2017-09-21 Dana Farber Cancer Institute, Inc. Inhibition of MCL-1 and/or BFL-1/A1
CA3113959A1 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
WO2014055564A1 (en) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EP3782638A1 (en) 2013-03-13 2021-02-24 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
CA2906775A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
WO2014144148A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
WO2014197821A1 (en) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
WO2014201370A1 (en) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN114805527A (zh) 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
EP3270945A4 (en) 2015-03-18 2018-09-05 Massachusetts Institute of Technology Selective mcl-1 binding peptides
EP3310373A4 (en) 2015-06-22 2019-02-13 University of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
US10464975B2 (en) 2015-07-02 2019-11-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
JP7049989B2 (ja) 2015-08-28 2022-04-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｆｌ－１と結合するペプチド
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
US10280317B2 (en) 2016-07-07 2019-05-07 Northwestern University Enhanced conductivity, adhesion and environmental stability of printed graphene inks with nitrocellulose
US11034720B2 (en) * 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
BR112020004555A2 (pt) 2017-09-07 2020-09-24 Fog Pharmaceuticals, Inc. agentes que modulam funções de beta-catenina e métodos dos mesmos
AU2019326423A1 (en) 2018-08-20 2021-04-08 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
CA3159729A1 (en) 2019-12-11 2021-06-17 Amrita Singh CHANDHOKE Technologies useful for assessing permeability
EP4121082A4 (en) 2020-03-17 2024-05-01 Fog Pharmaceuticals, Inc. HELICALLY STAPLED PEPTIDES AND USES THEREOF
CA3186681A1 (en) 2020-07-22 2022-01-27 Brian Halbert WHITE Stapled peptides and methods thereof
CN116113621A (zh) 2020-07-22 2023-05-12 弗格制药有限公司 氨基酸
BR112023025528A2 (pt) 2021-06-08 2024-02-27 Fog Pharmaceuticals Inc Peptídeos grampeados e métodos destes
US20240376151A1 (en) 2022-10-31 2024-11-14 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
US20260207704A1 (en) 2022-12-15 2026-07-23 Parabilis Medicines, Inc. Stapled peptides and methods thereof
WO2024130217A1 (en) 2022-12-15 2024-06-20 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof

Also Published As

Publication number Publication date
EA202190531A1 (ru) 2021-08-09
KR20210060482A (ko) 2021-05-26
SG11202101672YA (en) 2021-03-30
US12398178B2 (en) 2025-08-26
BR112021003113A2 (pt) 2021-05-11
US20210179665A1 (en) 2021-06-17
WO2020041270A1 (en) 2020-02-27
EP3840766A1 (en) 2021-06-30
EP3840766A4 (en) 2022-06-22
WO2020041270A9 (en) 2020-05-07
IL280931A (en) 2021-04-29
JP2021535108A (ja) 2021-12-16
CA3110082A1 (en) 2020-02-27
MX2021001943A (es) 2021-07-15
CN113039195A (zh) 2021-06-25
MA53446A (fr) 2021-06-30

Similar Documents

Publication Publication Date Title
US11834482B2 (en) Agents modulating beta-catenin functions and methods thereof
TWI918605B (zh) 作為治療劑之細胞毒素之肽結合物
JP4629036B2 (ja) アリールアルキルアミン化合物及びその製法
US12398178B2 (en) Collections of peptides, peptide agents, and methods of use thereof
ES2824801T3 (es) Sal de compuesto heterocíclico sustituido con halógeno
JP2021504314A (ja) Ｍｙｓｔファミリーヒストンアセチルトランスフェラーゼ阻害剤
WO2022261257A1 (en) Stapled peptides and methods thereof
EP4357339A1 (en) Sulfoximide substituted indazole irak4 kinase inhibitor, preparation method therefor, and use thereof
TW201109336A (en) Inhibitors of JNK
US20240376151A1 (en) Stapled peptides and methods thereof
CN112341390B (zh) 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途
CN120529912A (zh) 订书钉化肽及其方法
CN120513097A (zh) 订书钉化肽及其方法
WO2019157959A1 (zh) 一种嘧啶类化合物、其制备方法及其医药用途
HK40056052A (en) Collections of peptides, peptide agents, and methods of use thereof
CN115322120A (zh) 一类小分子化合物及在制备治疗dhodh介导疾病药物中的用途
JP7863272B2 (ja) フルオロアルコキシアルキレン－ジヒドロイミダゾ［５，１－ｄ］テトラジノン化合物および関連化合物ならびに医学的症状の治療におけるそれらの使用
HK40128981A (zh) 订书钉化肽及其方法
HK40108355A (en) Stapled peptides and methods thereof
HK40033762A (en) Agents modulating beta-catenin functions and methods thereof
CN117946165A (zh) 一种新型结构化合物axl抑制剂及其应用
KR101713678B1 (ko) 신규 화합물 4-Ethyl-7-(2-fluoro-benzylsulfanyl)-2-methyl-1-thia-3b, 5, 6-triaza-cyclopenta[a]indene 및 이를 포함하는 항암제용 약제학적 조성물
HK40129633A (en) Preparation of phenethylamines and cathinones and stereoisomers thereof and precursors thereof
WO2024131918A1 (zh) 一种取代草酰胺类衍生物、其制备方法及用途
BR112016030018B1 (pt) Sal composto de heterocíclico substituído com halogênio, antagonista do receptor de lpa, composição farmacêutica e uso do referido sal

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application